D'Orazio & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

D'Orazio & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$206K	Buy	+414	New	+$183K	0.02%	292

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

D'Orazio & Associates's VRTX Position: Q2 2026 in Review

D'Orazio & Associates opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 414 shares worth $206K. The stake represents 0.02% of the portfolio and ranks #292 among its holdings.

1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

D'Orazio & Associates held 414 shares of Vertex Pharmaceuticals worth $206K as of Q2 2026.
Vertex Pharmaceuticals was a new D'Orazio & Associates position in Q2 2026.
Vertex Pharmaceuticals made up 0.02% of D'Orazio & Associates's portfolio in Q2 2026, its #292 holding.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on D'Orazio & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.